Midatech (Biodexa Pharmaceuticals PLC) is focused on developing innovative treatments for diseases with significant unmet medical needs. Their lead product, eRapa™, is an oral formulation of rapamycin (sirolimus), which acts as an mTOR inhibitor. This technology aims to enhance the bioavailability and pharmacokinetics of rapamycin, which is known for its role in regulating cellular metabolism and growth, particularly in the context of tumorigenesis. By utilizing nanotechnology and pH-sensitive polymers, eRapa™ seeks to overcome the challenges associated with the poor water solubility of rapamycin and the variability in systemic plasma levels seen in existing formulations. This product is currently being prepared for a phase 3 registration study targeting familial adenomatous polyposis (FAP), a condition that can lead to colorectal cancer if left untreated.

In addition to eRapa™, Biodexa is also developing Tolimidone, an orally delivered inhibitor of lyn kinase, which is involved in glycemic control and has shown promise in animal models for type 1 diabetes. This compound has the potential to be a first-in-class agent for modulating blood glucose levels. Furthermore, the company is exploring treatments for primary and metastatic brain cancers, indicating a broad commitment to addressing various serious health conditions through their advanced biopharmaceutical pipeline.

United Kingdom

An R&D company focused on delivering innovative oncology and rare disease products to patients. Midatech has three platform technologies that are focused on improving bio-distribution and bio-delivery of medications in different ways – either via sustained delivery, targeted delivery, or direct delivery. These are: microspheres, saccaride nanoparticles, and gold nanoparticles.

Midatech(Biodexa)

Company Details